Ga direct naar de inhoud

Ga direct naar de navigatie

Uitgave van

Archief voor de categorie ‘Overnames’

GlaxoSmithKline aims for the whole consumer-health shebang with $10.3B Novartis JV buyout

Next March, GlaxoSmithKline will have the option to buy out Novartis’ stake in the pair’s industry-leading consumer health JV. And it may already be getting prepared. The British drugmaker is getting its ducks in a row for an £8 billion ($10.3 billion) offer for its partner’s 36.5% share, top shareholders told The Sunday Times.

Bron: FiercePharma Meer lezen »

Sanofi is a ‘satisfactory’ business with no urgent M&A needs, chairman says

Sanofi Chairman Serge Weinberg says he likes what his company is achieving and that he doesn’t think the drugmaker needs a major M&A deal to meet its goals. Coming at an annual meeting this week, his remarks echoed recent sentiment shared by CEO Olivier Brandicourt.

Bron: FiercePharma Meer lezen »

Is Pfizer really weighing a BMS buy? Clues from Q1’s earnings call say it just may be

Is Pfizer thinking of buying Bristol-Myers Squibb, as the rumors go? CEO Ian Read hinted at the possibility on Tuesday’s first-quarter earnings call—but investors shouldn’t expect any immediate action, he cautioned. As Read told shareholders on the call, “we … believe we have the ability, should the opportunity arise and should the value be there, to […]

Bron: FiercePharma Meer lezen »

Deal Watch March 2017

Each month the Deal Watch team ploughs our merry way through the details of 600 plus deals to bring you the edited highlights. This March the total number was high (well over 700), but the number of interesting and valuable deals was the lowest we have seen in a year.

Bron: PMLiVE Meer lezen »

Takeda lays off more than half of Ariad’s US staff

Takeda acquired Ariad Pharmaceuticals at the beginning on the year for $5.2 billion, a price many thought was relatively high but satisfied Takeda’s well-known desire to bolster its business with an acquisition. As often happens after a takeover, however, the job cuts have begun – with Takeda having shed 180 staff from a total of […]

Bron: Meer lezen »

Sanofi looks to close $1 billion deal Flexion

According to reports emerging, Sanofi may be on the verge of closing a deal with Burlington-based biotech, Flexion Therapeutics. The deal is thought to be valued at around $1 billion and could potentially close quickly, with Flexion’s board thought to have agreed to the offer but with the finer details still be smoothed through.

Bron: Meer lezen »

Merck confirms sale of biosimilar division

Merck KGaA has confirmed it intends to sell off its biosimilar drugs division, and is in “advanced discussions” with potential buyers. The German group kicked off its biosimilar programme in 2012 via an agreement with India’s Dr Reddy’s Laboratories, at a time when the company was facing patent expiries on some big-selling products.

Bron: PMLiVE Meer lezen »

Novo Nordisk eyes acquisition of Global Blood Therapeutics

Novo Nordisk has been notoriously shy when it comes to making acquisitions but Reuters has reported that this may be set to change. According to reports, Novo Nordisk has approached Global Blood Therapeutics, a US-based biotech company focusing on blood disorders, to discuss a potential takeover.

Bron: Meer lezen »

Chinese drugmakers, PE firms—even, reportedly, a Big Pharma—pile into Stada deal action

The race to snatch up generics maker Stada is heating up—and fast. Just over two weeks after Boston private equity outfit Advent International put up the first legally binding bid for the drugmaker, multiple players are reportedly preparing to jump into the fray.  

Bron: FiercePharma Meer lezen »

Thwarted buyer Sanofi tries its hand at a $2.1B European generics sale

After losing out on two sizable deals, Sanofi CEO Olivier Brandicourt recently said his company wasn’t looking to make any big M&A moves right away. Instead, Sanofi might be looking to slim down by prepping the sale of its European generics unit, according to a new report.

Bron: FiercePharma Meer lezen »

« Oudere artikelen |